Clinical Trial Update: Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker [Phase 2]

View source ↗

Summary

Phase 2 trial investigating pembrolizumab in metastatic melanoma with CT texture analysis as a predictive biomarker; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Metastatic Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2019-09-20